News

Phase III data for eye drug
Enlarge image

Clinical TrialsBelgium

Phase III data for eye drug

17.08.2012 - Belgian biopharmaceutical company ThromboGenics N.V. published encouraging data from two Phase III studies with its eye treatment experimental drug Ocriplasmin.

The studies published in New England Journal of Medicine (NEJM) including in total 652 patients found that the recombinant protein significantly resolved vitreomacular traction and closed macular holes compared to placebo in patients with vitreomacular adhesion (VMA). A health care practitioner, who treated patients in one of the studies said ocriplasmin could help a significant number of patients at an earlier point in their disease and improve their vision much more than surgery, which is the current standard of care.

"Results from the phase III programme with ocriplasmin are significant as they demonstrate the potential for using an enzymatic approach to resolve vitreomacular adhesion. This represents a real advance for patients living with vitreomacular adhesion who currently only have the option of surgery at a later stage of the disease," said Peter Stalmans, Department of Ophthalmology, University Hospitals, Leuven, Belgium. "The majority of patients who achieved resolution of their vitreomacular adhesion after a single intravitreal injection of ocriplasmin showed this positive outcome within the first seven days."

Ocriplasmin is a recombinant, truncated form of human plasmin that works by dissolving the proteins that link the vitreous to the macula. If approved, the drug, couldbecome the first pharmaceutical treatment for vitreomacular adhesion (VMA). Currently vitrectomy, or surgical removal of the vitreous from the eyeball, is the only available treatment for VMA. In patients with VMA, the vitreous adheres in an abnormally strong way to the retina, which can lead to traction on the retina, causing symptoms including impaired vision. Further unresolved traction may lead to the development of macular holes and central blindness.Thrombogenics developed the biologic and plans to market ocriplasmin on its own in the US. In a deal worth up to €300m in milestone payments and royalties Swiss drug maker Novartis’ subsidiary Alcon paid €75m up front in March to license the ex-US rights to the drug, which is currently under review by FDA and EMA.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

BioeconomyFranceEU

01.04.2014 The European Commission has approved a French state package aid worth €43m for green chemistry project IEED.

MonitoringEU

27.03.2014 In Europe, bacterial resistance to prevalent antimicrobials is common, while multi-resistance remains low, EFSA and ECDC now report.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MORPHOSYS (D)62.00 EUR11.8%
  • BIOINVENT INTERNATIONAL AB (S)2.96 SEK10.9%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%

FLOP

  • CYTOS (CH)0.17 CHF-26.1%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)9.94 USD-9.7%

TOP

  • WILEX (D)0.92 EUR61.4%
  • CO.DON (D)3.30 EUR61.0%
  • BIOTECH PHARMACON (N)17.50 NOK59.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.9%
  • BIONOR PHARMA (N)2.11 NOK-47.6%
  • GW PHARMACEUTICALS (UK)219.25 GBP-40.4%

TOP

  • SILENCE THERAPEUTICS (UK)256.00 GBP6221.0%
  • IXICO (UK)71.50 GBP810.8%
  • PHARMING (NL)0.47 EUR683.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-92.5%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 18.04.2014